Evaluation of periodontal treatments using controlled-release tetracycline fibers: microbiological response.
In a 12-month multi-center study of 116 adult periodontitis subjects, six putative periodontal pathogens were monitored by DNA probe methods in a subset of 31 subjects. Monitored species included Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Eikenella corrodens (Ec), Campylobacter rectus (Cr), and Actinobacillus actinomycetemcomitans (Aa) with an average detection limit of 1.8 x 10(4) bacterial colony forming units/sample. The microbiological response to four periodontal treatments was studied, one treatment in each quadrant; scaling and root planing (S), scaling and root planing with tetracycline (TC) fiber (SF), a single application of TC fiber (F) and two serial applications of TC fiber (FF). Generally two sites were sampled in each quadrant, however, in some quadrants only one site was selected. These treatments were evaluated at baseline; immediately following therapy; and post-treatment at 1, 3, 6, and 12 months. The study was conducted with a split-mouth design with no maintenance therapy over a 12-month period. At baseline, 70.8% of sites had detectable Fn; 42.9% Pg; 63.5% Pi; 29.7% Ec; 28.3% Cr; and 5.5% Aa. No significant differences were seen in baseline proportions of these species between centers. Numbers and proportions of detectable pathogens (with the exception of Pg) exhibited a triphasic temporal response: a precipitous initial decrease immediately following therapy; a rise in proportions in the 1- to 3-month post-therapy period; and a spontaneous decline in the absence of therapy over the 3- to 12-month period.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000368:Aged; D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D002167:Campylobacter / Q000187:drug effects / Q000302:isolation & purification; D015169:Colony Count, Microbial; D003131:Combined Modality Therapy; D015342:DNA Probes; D003692:Delayed-Action Preparations; D012534:Dental Scaling; D004343:Drug Implants; D016124:Eikenella corrodens / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D005500:Follow-Up Studies; D016967:Fusobacterium nucleatum / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010518:Periodontitis / Q000188:drug therapy* / Q000382:microbiology*; D016966:Porphyromonas gingivalis / Q000187:drug effects / Q000302:isolation & purification; D018713:Prevotella intermedia / Q000187:drug effects / Q000302:isolation & purification; D016745:Root Planing; D016037:Single-Blind Method; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D015342:DNA Probes; D003692:Delayed-Action Preparations; D004343:Drug Implants; D013752:Tetracycline